Current Hematologic Malignancy Reports

, Volume 13, Issue 2, pp 69–77 | Cite as

Frontline Therapy of CLL: Evolving Treatment Paradigm

Chronic Lymphocytic Leukemias (N Jain, Section Editor)
  • 426 Downloads
Part of the following topical collections:
  1. Topical Collection on Chronic Lymphocytic Leukemias

Abstract

Purpose of Review

Chronic lymphocytic leukemia (CLL) has multiple current frontline therapy options, including chemoimmunotherapy (CIT) and most recently, ibrutinib. Here, we review the most recent updates in the frontline treatment of CLL, including updates in CIT, updates in targeted therapies, and ongoing clinical trials.

Recent Findings

Ibrutinib was FDA-approved for the upfront treatment of CLL in 2016 after being studied in older patients and those with 17p deletions or TP53 mutations. The introduction of ibrutinib has dramatically changed the treatment paradigm of CLL.

Summary

Recent updates in CIT include that immunoglobulin heavy chain variable (IGHV) gene mutation status is strongly predictive of response to CIT. Regarding targeted therapy, next-generation BTK and PI3K inhibitors are currently being studied in the upfront treatment of CLL, which may have less toxicity than their first-generation counterparts. Other novel targeted therapies are being studied in the frontline setting, most notably venetoclax including in combinations, with hopes to achieve chemotherapy-free, time-limited treatment options. Multiple key ongoing phase 3 clinical trials will be answering these important clinical questions.

Keywords

CLL Chronic lymphocytic leukemia Frontline First-line Upfront Treatment 

Notes

Compliance with Ethical Standards

Conflict of Interest

Craig S. Boddy declares no potential conflicts of interest.

Shuo Ma reports personal fees from Pharmacyclics, Genetech, Abbvie, Gilead, and AstraZeneca and grants from Pharmacyclics, Abbvie, Gilead, AstraZeneca, Celgene, Xeme, and NCCN.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    SEER Cancer Stat Facts Chronic lymphocytic leukemia, MD http://seer.cancer.gov/statfacts/html/clyl.html. Accessed 27 Nov 2017.
  2. 2.
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.  https://doi.org/10.1182/blood-2007-06-093906.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    •• Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.  https://doi.org/10.1056/NEJMoa1509388. This is a very important reference since it led to the FDA approval of ibrutinib as a frontline therapy in all patients with CLL—the first and only FDA-approved targeted frontline therapy in CLL. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    • Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–76.  https://doi.org/10.1016/S1470-2045(14)71182-9. This is also a very important reference for ibrutnib, showing its efficacy in 17p- or TP53-mutated patients patients that are very difficult to otherwise treat. CrossRefPubMedGoogle Scholar
  5. 5.
    Ghia P, Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: right track or red herring? Blood. 2012;119(19):4358–62.  https://doi.org/10.1182/blood-2012-01-404681.CrossRefPubMedGoogle Scholar
  6. 6.
    Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7415):309–12.  https://doi.org/10.1038/nature11309.CrossRefPubMedGoogle Scholar
  7. 7.
    Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563–74.  https://doi.org/10.1182/blood-2010-05-284984.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009;114(5):1029–37.  https://doi.org/10.1182/blood-2009-03-212837.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175–84.  https://doi.org/10.1182/blood-2012-02-362624.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev. 2009;228(1):132–48.  https://doi.org/10.1111/j.1600-065X.2008.00748.x.CrossRefPubMedGoogle Scholar
  11. 11.
    Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32.  https://doi.org/10.1056/NEJMoa1509981. CrossRefPubMedGoogle Scholar
  12. 12.
    O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–18.  https://doi.org/10.1016/s1470-2045(16)30212-1.CrossRefPubMedGoogle Scholar
  13. 13.
    Tam CS, Quach H, Nicol A, Badoux X, Rose H, Prince H, et al. Safety and activity of the highly specific BTK inhibitor, BGB-3111 plus obinutuzumab in patients (PTS) with follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Hematol Oncol. 2017;35:113.  https://doi.org/10.1002/hon.2437_102.CrossRefGoogle Scholar
  14. 14.
    Flinn IW, O’Brien S, Kahl B, Patel M, Oki Y, Foss FF, et al. Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies. Blood. 2017:blood-2017-05-786566.  https://doi.org/10.1182/blood-2017-05-786566.
  15. 15.
    Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.  https://doi.org/10.1056/NEJMoa1315226. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Robak P, Robak T. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26(11):1249–65.  https://doi.org/10.1080/13543784.2017.1384814.CrossRefPubMedGoogle Scholar
  17. 17.
    Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82(6):1820–8.PubMedGoogle Scholar
  18. 18.
    Papakonstantinou G, Verbeke C, Hastka J, Bohrer M, Hehlmann R. bcl-2 expression in non-Hodgkin’s lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol. 2001;113(2):383–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348(6299):334–6.  https://doi.org/10.1038/348334a0.CrossRefPubMedGoogle Scholar
  20. 20.
    • Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.  https://doi.org/10.1056/NEJMoa1513257. An important reference demonstrating venteoclax’s impact in CLL, which may revolutionize how CLL is treated in the future. CrossRefPubMedGoogle Scholar
  21. 21.
    • Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.  https://doi.org/10.1016/s1470-2045(16)30019-5. An important reference demonstrating venteoclax’s impact in CLL, which may revolutionize how CLL is treated in the future. CrossRefPubMedGoogle Scholar
  22. 22.
    Chronic lymphocytic leukemia/small lymphocytic lymphoma. National Comprehensive Cancer Network (NCCN). https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed 1 Dec 2017.
  23. 23.
    • Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247–54.  https://doi.org/10.1182/blood-2014-01-546150. Important reference showing FCR’s efficacy based on IGHV mutation status. CrossRefPubMedGoogle Scholar
  24. 24.
    Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (London, England). 2010;376(9747):1164–74.  https://doi.org/10.1016/s0140-6736(10)61381-5.CrossRefGoogle Scholar
  25. 25.
    • Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980–8.  https://doi.org/10.1200/jco.2011.36.9348. This sudy shows the correlation with attaining MRD negativity and long-term outcomes when treated with FCR. CrossRefPubMedGoogle Scholar
  26. 26.
    Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42.  https://doi.org/10.1016/S1470-2045(16)30051-1.CrossRefPubMedGoogle Scholar
  27. 27.
    Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.  https://doi.org/10.1056/NEJMoa1313984. CrossRefPubMedGoogle Scholar
  28. 28.
    Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32(12):1236–41.  https://doi.org/10.1200/jco.2013.49.6547.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Foa R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014;89(5):480–6.  https://doi.org/10.1002/ajh.23668.CrossRefPubMedGoogle Scholar
  30. 30.
    Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15.  https://doi.org/10.1182/blood-2015-06-651125.CrossRefPubMedGoogle Scholar
  31. 31.
    Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921–4.  https://doi.org/10.1182/blood-2015-05-647925.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    • Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–9.  https://doi.org/10.1182/blood-2015-09-667675. This study shows a tail on the Kaplan-Meier curve of possible cures in young, IGHV-mutated CLL patients treated with FCR. CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56(6):1643–50.  https://doi.org/10.3109/10428194.2014.957203.CrossRefPubMedGoogle Scholar
  34. 34.
    Eichhorst BF BJ, Maurer C, Lange E, Köppler H, et al. Favorable toxicity profile and long-term outcome of elderly, but physically fit CLL patients (pts) receiving first line bendamustine and rituximab (BR) frontline chemoimmunotherapy in comparison to fludarabine, cyclophosphamide, and rituximab (fcr) in advanced chronic lymphocytic leukemia (CLL): update analysis of an international, randomized study of the German CLL study group (GCLLSG) (CLL10 Study). Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 4382.Google Scholar
  35. 35.
    Voorhies BN, Stephens DM. What is optimal front-line therapy for chronic lymphocytic leukemia in 2017? Curr Treat Options in Oncol. 2017;18(2):12.  https://doi.org/10.1007/s11864-017-0450-8. CrossRefGoogle Scholar
  36. 36.
    Brown JR, O’Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, et al. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015;125(18):2779–85.  https://doi.org/10.1182/blood-2014-12-613570.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sharman JPYH, Boxer M, DiBella N, Babu S, Li J, Mun YJ, et al. Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL). J Clin Oncol. 2017;35(suppl):abstr 7523.Google Scholar
  38. 38.
    Flinn IW, Panayiotidis P, Afanasyev B, Janssens A, Grosicki S, Homenda W, et al. A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. Am J Hematol. 2016;91(9):900–6.  https://doi.org/10.1002/ajh.24430.CrossRefPubMedGoogle Scholar
  39. 39.
    Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7):1602–4.  https://doi.org/10.1038/leu.2015.14.CrossRefPubMedGoogle Scholar
  40. 40.
    Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016;127(1):79–86.  https://doi.org/10.1182/blood-2015-03-634394.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Flinn IW, Ruppert AS, Harwin W, Waterhouse D, Papish S, Jones JA, et al. A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia. Am J Hematol. 2016;91(10):1020–5.  https://doi.org/10.1002/ajh.24468.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Frankfurt O, Ma S, Gordon L, Winter JN, Horowitz JM, Rademaker A, et al. Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes. Leuk Lymphoma. 2015;56(2):315–23.  https://doi.org/10.3109/10428194.2014.910654.CrossRefPubMedGoogle Scholar
  43. 43.
    Fink AM BJ, Sandra R, Al-Sawaf O, Aldaoud A et al. Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk cll: interim results of a phase 3 study (CLL M1 study of the German CLL Study Group). Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 229.Google Scholar
  44. 44.
    Ruppert ASBJ, Heerema NA, Smith MR, Godwin JE, Couban S, Fehniger TA, et al. A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): results from cancer and leukemia group B (CALGB) 10404 (Alliance). J Clin Oncol. 2017;35(suppl):abstr 7503.Google Scholar
  45. 45.
    Greil R, Obrtlikova P, Smolej L, Kozak T, Steurer M, Andel J, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016;3(7):e317–29.  https://doi.org/10.1016/S2352-3026(16)30045-X.CrossRefPubMedGoogle Scholar
  46. 46.
    Mato AR, Foon KA, Feldman T, Schuster SJ, Svoboda J, Chow KF, et al. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol. 2015;90(6):487–92.  https://doi.org/10.1002/ajh.23983.CrossRefPubMedGoogle Scholar
  47. 47.
    O’Brien SM FR, Coutre SE, Flinn IW, et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 233.Google Scholar
  48. 48.
    Barr P RT, Owen CJ, Tedeschi A, et al. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 234.Google Scholar
  49. 49.
    Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940–3.  https://doi.org/10.1182/blood-2016-06-722991.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Sese L, Rivaud E, Bron C, Leblond V, Raffoux E, Longchampt E, et al. Unexpected pneumocystis jirovecii pneumonia in patients with untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2017:1–4.  https://doi.org/10.1080/10428194.2017.1357170.
  51. 51.
    Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128(2):195–203.  https://doi.org/10.1182/blood-2016-03-707133.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686–94.  https://doi.org/10.1182/blood-2015-03-630947.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, et al. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016;122(16):2505–11.  https://doi.org/10.1002/cncr.30069.CrossRefPubMedGoogle Scholar
  54. 54.
    Gilead Sciences. Direct Healthcare Professional Communication. Restrictions on the use of Zydelig® (idelalisib) for the treatment of chronic lymphocytic leukaemia (CLL) and relapsed follicular lymphoma (FL) following new clinical trial results. March 23, 2016.Google Scholar
  55. 55.
    Amaya-Chanaga CI CM, Nguyen N, DeVore E, MacCarthy C, et al. A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions. Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 2048.Google Scholar
  56. 56.
    Rawstron AC MT, Muñoz-Vicente S, Brock K, Yates FJ, et al. Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study. Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 2049.Google Scholar
  57. 57.
    von Tresckow J CP, Bahlo J, Robrecht S, Engelke A, et al. CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 640.Google Scholar
  58. 58.
    Davids MS KH, Brander DM, Bsat J, Savell A, et al. Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 3243.Google Scholar
  59. 59.
    Jain NTP, Burger JA, Borthakur G, Bose P, Estrov Z, et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p). J Clin Oncol. 2017;35(suppl):abstr 7522.Google Scholar
  60. 60.
    • Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230–40.  https://doi.org/10.1016/s1470-2045(17)30012-8. This study shows very signficant rates of MRD negativity in relapsed CLL patients treated with this novel combination, which questions how it fare would if incorporated as a frontline therapy. CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Fischer K A-SO, Fink AM, Dixon M, Bahlo J, et al. Safety and efficacy of venetoclax and obinutuzumab in patients with previously untreated chronic Lymphocytic leukemia (CLL) and coexisting medical conditions: final results of the run-in phase of the randomized CLL14 trial (BO25323). Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 2054.Google Scholar
  62. 62.
    Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702–5.  https://doi.org/10.1182/blood-2017-01-761973.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Ghia P, Tam CS, Siddiqi T, Stevens D, Flinn IW, Russell K, et al. An ongoing phase 2 study of ibrutinib combined with venetoclax in patients with treatment-naïve CLL/SLL. Hematol Oncol. 2017;35:428.  https://doi.org/10.1002/hon.2440_13.CrossRefGoogle Scholar
  64. 64.
    Stilgenbauer S MF, Wendtner CM, Cartron G, Hallek M, et al. Phase Ib Study (GO28440) of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 4393.Google Scholar
  65. 65.
    Cramer P, von Tresckow J, Bahlo J, Robrecht S, Al-Sawaf O, Langerbeins P, et al. Bendamustine (b), followed by obinutuzumab (g) and venetoclax (a) in patients with chronic lymphocytic leukemia (CLL): CLL2-bag trial of the German CLL Study Group (GCLLSG). Hematol Oncol. 2017;35:25–7.  https://doi.org/10.1002/hon.2437_5.CrossRefGoogle Scholar
  66. 66.
    Cramer P vTJ, Bahlo J, Robrecht S, Engelke A, et al. Low incidence of tumor lysis syndromes (TLS) and infusion related reactions (IRR) in the CLL2-bag trial evaluating a sequential treatment of bendamustine (B), obinutuzumab (GA101, G) and venetoclax (ABT-199, A) in patients with chronic lymphocytic leukemia (CLL): interim safety results of a phase-II-trial of the German CLL Study Group (GCLLSG). Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 2044.Google Scholar
  67. 67.
    Strati P TP, Keating M, Hinojosa C, Rodriguez D, et al. A phase II study of the combination of lenalidomide and rituximab in patients with treatment-naïve and relapsed chronic lymphocytic leukemia. Blood Abstracts: 58th Annual Meeting Abstracts. 2016;128(22):abstr 4389.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer CenterNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer CenterNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations